RELMADA THERAPEUTICS, INC. 10-Q

ITEM 5. OTHER INFORMATION None. 23 ITEM 6. EXHIBITS Copies of the following documents are included as exhibits to this report pursuant to Item 601 of Regulation S-K Exhibit No. Title of Document Location 10.1 Relmada Therapeutics, Inc. 2021 Equity Incentive Plan Exhibit 10.1 to Current Report on Form 8-K filed on May 20, 2021 10.2 License Agreement dated as of July 16, 2021, between Arbormentis, LLC and Relmada Therapeutics, Inc.* Filed Herewith 31.1 Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Filed herewith 31.2 Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Filed herewith 32.1 Certification of the Chief Executive Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002** Furnished herewith 32.2 Certification of the Principal Financial Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002** Furnished herewith 101.INS Inline XBRL Instance Document. Filed herewith 101.SCH Inline XBRL Taxonomy Extension Schema Document. Filed herewith 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document. Filed herewith 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document. Filed herewith 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document. Filed herewith 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document. Filed herewith 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). Filed herewith * Certain information identified by [***] has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. ** The Exhibit attached to this Form 10-Q shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. 24 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: August 10, 2021 By: /s/ Sergio Traversa Sergio Traversa Chief Executive Officer (Duly Authorized Officer and Principal Executive Officer) /s/ Maged Shenouda Maged Shenouda Chief Financial Officer (Duly Authorized Officer and Principal Financial and Accounting Officer) 25